Free Trial
NASDAQ:DNTH

Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

Dianthus Therapeutics logo
$20.59 -0.08 (-0.39%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$21.00 +0.41 (+1.99%)
As of 08/1/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dianthus Therapeutics Stock (NASDAQ:DNTH)

Key Stats

Today's Range
$20.00
$21.42
50-Day Range
$16.85
$22.28
52-Week Range
$13.36
$32.27
Volume
370,878 shs
Average Volume
352,897 shs
Market Capitalization
$662.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00
Consensus Rating
Buy

Company Overview

Dianthus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

DNTH MarketRank™: 

Dianthus Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 818th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Dianthus Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Dianthus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dianthus Therapeutics is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dianthus Therapeutics is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dianthus Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dianthus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    27.33% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently decreased by 10.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Dianthus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dianthus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    27.33% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 20.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently decreased by 10.95%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Dianthus Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 4 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dianthus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.15% of the stock of Dianthus Therapeutics is held by insiders.

  • Percentage Held by Institutions

    47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dianthus Therapeutics' insider trading history.
Receive DNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DNTH Stock News Headlines

This Crypto Is Set to Explode in January
Free summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…
See More Headlines

DNTH Stock Analysis - Frequently Asked Questions

Dianthus Therapeutics' stock was trading at $21.80 at the beginning of the year. Since then, DNTH shares have decreased by 5.6% and is now trading at $20.59.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings results on Monday, May, 12th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.04. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,544.23% and a negative trailing twelve-month return on equity of 29.26%.

Dianthus Therapeutics' top institutional shareholders include AlphaQuest LLC (0.02%). Insiders that own company stock include Fairmount Funds Management Llc and Simrat Randhawa.
View institutional ownership trends
.

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
5/12/2025
Today
8/02/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DNTH
CIK
1690585
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$84.00
Low Price Target
$36.00
Potential Upside/Downside
+157.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$84.97 million
Net Margins
-1,544.23%
Pretax Margin
-1,544.26%
Return on Equity
-29.26%
Return on Assets
-27.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.98
Quick Ratio
15.99

Sales & Book Value

Annual Sales
$6.24 million
Price / Sales
106.12
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.91 per share
Price / Book
1.73

Miscellaneous

Outstanding Shares
32,160,000
Free Float
29,539,000
Market Cap
$662.17 million
Optionable
Optionable
Beta
1.43
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:DNTH) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners